Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
about
Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neuronsSIP, a novel ankyrin repeat containing protein, sequesters steroid receptor coactivators in the cytoplasmThe molecular mechanism governing the oncogenic potential of SOX2 in breast cancerZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylasesZIP: a novel transcription repressor, represses EGFR oncogene and suppresses breast carcinogenesisGAS, a new glutamate-rich protein, interacts differentially with SRCs and is involved in oestrogen receptor functionRegulation of specific target genes and biological responses by estrogen receptor subtype agonistsTherapeutic options for management of endometrial hyperplasiaSex-specific lung diseases: effect of oestrogen on cultured cells and in animal modelsClinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifenEnvironmental toxicants, epigenetics, and cancerIcaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cellsMetabolomic profiling unravels DNA adducts in human breast that are formed from peroxidase mediated activation of estrogens to quinone methidesA model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen.Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trialsERβ selective agonist inhibits angiotensin-induced cardiovascular pathology in female micePGF2α-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer.ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesityMolecular clustering of endometrial carcinoma based on estrogen-induced gene expression.Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer.Hypermethylation of SOX2 Promoter in Endometrial Carcinogenesis.CCCTC-binding factor acts upstream of FOXA1 and demarcates the genomic response to estrogen.Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesisFunctional variants at the 21q22.3 locus involved in breast cancer progression identified by screening of genome-wide estrogen response elements.Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer developmentConstruction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.Estrogen receptor mutations and their role in breast cancer progressionBiomarkers in endometrial cancer: Possible clinical applications (Review)APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer.Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elementsThe effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.Maternal smoking impacts key biological pathways in newborns through epigenetic modification in Utero.Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signalingEstrogen-responsive genes encoding egg yolk proteins vitellogenin and apolipoprotein II in chicken are differentially regulated by selective estrogen receptor modulators.Does the radiofrequency impedance-controlled endometrial ablation have any morphologic effects on uterine leiomyomata? Report of 3 cases.Bioactivation of Selective Estrogen Receptor Modulators (SERMs)Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.
P2860
Q21562188-881A0BE2-387D-4D5A-8BB5-F3BE36356F05Q24304823-4C076112-A34E-493F-9F29-A4954DA672AAQ24309520-AA4FE927-7F3D-4369-B519-095F8122439CQ24312025-4F7C9035-C522-41E2-96F0-12234D1AA4E7Q24318720-3E5874D9-885D-4C0E-B71E-EABA9496BBC9Q24318938-314B7C14-6BDD-4730-B42A-74168BEF328EQ24621003-05DEF818-3B3C-43FA-A258-9D8317495695Q26783569-DA6E8028-2BBE-4C6F-94CD-2D03BCDEBF08Q27687650-63EB9ABF-E0C1-4454-8BF8-E83275FB03D0Q28281218-7F970A6C-EFFE-46D8-AD26-5A9FB2E70DF5Q28385295-FF63044A-0CB9-444F-9761-FA7331408C8DQ28477353-1ED43323-ACDE-47B0-8E6A-F8A50C1F3331Q28533703-3DDCFE89-DCF5-4310-94FD-AE98D9A6582AQ30535835-59B4856F-B6ED-49F5-B3FF-207A04EB5C4DQ33579159-4DBFCAB5-AF37-49A4-BA0F-F73564290A34Q33584903-CD7641F0-31D6-46D9-8DD1-60BF6609D5FDQ33692377-2CA0F115-92C3-4905-B5AB-A9215EADDD2FQ33747888-98DDE46C-C34F-4088-AC7F-D8E0D5F31A93Q33829461-A23C4199-EF88-4BF3-8DCD-3F08E10CC7D2Q33858186-BBDDC9A1-477B-4643-8CF5-CD999859AF4CQ33894047-74124C1F-67DE-4FCA-B646-740EF2F85E0BQ34089736-F2F0CE95-91D5-419B-9CDE-982BBF9AD82BQ34121216-99070E6E-F9F9-4168-8418-7B7907CE8B63Q34628232-DCD4A9C9-2C94-480C-A08F-651E96F7448BQ34727321-1510A843-1EAF-4CD0-9B04-185184EC9618Q34938177-7BDA6E02-0ECB-4198-9E2B-6F37A0B8FE26Q35000343-5D5C4B1B-3EC5-4A19-899D-DB4735AB29A2Q35029561-042377FB-2878-492F-AC91-30CB85910A31Q35593300-D608AEFB-9574-4AE5-9A1F-3D474124BED4Q35599448-54FB43CE-21BD-44CC-8BF9-E5D145D4C339Q36084326-83396A25-ED3F-4FA9-B58E-6376109B5689Q36133842-FD027FBB-1756-4201-BE11-5A36658C0CA8Q36167236-47BA0F6F-4292-4BCF-9816-E5F26E9F2E9DQ36171217-112AE987-8216-419A-8DFF-C2EB7168E688Q36204093-BFE658E9-7D8A-4D90-9839-7D6BD3AD1441Q36212729-76A0DC9D-F64A-4041-B2DE-79657AB1BA0CQ36437107-F07BF1A1-DF58-4B35-9729-28BB3220D940Q36493879-50C81E74-DA3E-4695-98E5-D62CFF2214F9Q36595120-922B77CA-FD88-4EA8-ACCA-A00E993A157FQ36731191-69DEFF31-6D3D-4261-80DC-9CED2EB14CDA
P2860
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@ast
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@en
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@nl
type
label
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@ast
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@en
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@nl
prefLabel
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@ast
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@en
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@nl
P2860
P356
P1476
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
@en
P2093
Yongfeng Shang
P2860
P2888
P304
P356
10.1038/NRC1879
P407
P577
2006-05-01T00:00:00Z
P5875
P6179
1009898631